We are live on ! Find out more
AYTU icon

AYTU BioPharma
AYTU

Fund managers haven’t disclosed any holdings of AYTU yet.

AYTU Hedge Fund Activity: Q1 2026 in Review

37 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q1 2026, worth a combined $10.7M — up 8.7% from $9.81M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new AYTU positions and 5 closed out — a net gain of 1 holder — while 9 added to existing stakes and 5 trimmed.

The largest buyer was Crown Advisors Management, opening a new position worth an estimated $371K. The largest seller was FNY Investment Advisers, cutting an estimated $80.6K.

  • 37 institutional investors held AYTU BioPharma (AYTU) as of Q1 2026, down from 39 in Q4 2025.
  • Funds reported $10.7M of AYTU BioPharma stock for Q1 2026, up 8.7% quarter-over-quarter.
  • 6 funds opened new AYTU BioPharma positions in Q1 2026 and 5 closed out, a net change of +1 holder.
  • The largest AYTU BioPharma buyer in Q1 2026 was Crown Advisors Management, an estimated $371K added.
  • The largest AYTU BioPharma seller in Q1 2026 was FNY Investment Advisers, an estimated $80.6K sold.

Based on aggregated 13F filings for Q1 2026.